Re-PVI plus targeted CFA and DOA substrate ablation did not improve 1-year freedom from sustained atrial arrhythmia versus Re-PVI alone in persistent AF patients.
Does Re-PVI plus targeted substrate ablation guided by CFA and DOA mapping improve freedom from sustained atrial arrhythmia compared to Re-PVI alone in patients with persistent AF undergoing a second ablation?
In patients undergoing a second ablation for persistent AF, adding targeted substrate ablation guided by CFA and DOA mapping to Re-PVI did not improve freedom from atrial arrhythmias compared to Re-PVI alone.
Abstract Introduction Currently, no standard approach exists for persistent AF substrate ablation. Several substrate ablation methods such as targeting Continuous Fractionated Activity (CFA) and Dispersion of Activity (DOA) are explored but often lack rigorous validation in randomized setting. Purpose To assess whether Re-PVI plus targeted substrate ablation, guided by CFA and DOA mapping, improves long-term outcomes compared with Re-PVI alone in patients with persistent AF undergoing a second ablation procedure. Methods The AF CAM study is an investigator-initiated, prospective, randomized, open-label, blinded-endpoint, multi-center clinical trial. Patients with persistent AF (aged 18–85 years) undergoing a second ablation for AF recurrence were randomized 1:1 to either: Group A: Re-PVI alone or Group B: Re-PVI plus targeted ablation of areas scoring in the top 10% for CFA and/or DOA. 200 patients were planned to be randomized. Mapping was performed using high-resolution 8-spline multipolar basket catheter. Target areas were identified using custom algorithms that quantified CFA and DOA, with ablation performed until local electrogram amplitudes were reduced to 0.1 mV. The primary endpoint was freedom from any sustained atrial arrhythmia (30 sec) between 3 and 12 months follow-up, assessed via 12-lead ECGs, 48-hour Holter monitoring, and symptom-driven event monitoring. Results Between Aug 2021 and Nov 2023, we randomized 56 patients (mean age 68±10 years, 32% women, mean LA diameter 45±6 mm) to group A (n=28) and group B (n=28). Baseline characteristics and procedural data were comparable. The median procedure time was 87 71, 110 minutes for group A and 161 140, 218 minutes for group B. Recruitment was terminated early due to slow enrolment. Median follow-up was 12.09 11.24, 12.62 months. The 1-year Kaplan-Meier estimate for freedom from any sustained atrial arrhythmia was 62.7% 46.8%, 84.1% in group A (10 events) and 59.1% 42.3%, 82.4% in group B (10 events), with no difference between the groups. 85% of patients presented with reconnection of at least one pulmonary vein. Pulmonary vein reconnection did not have an effect on the primary endpoint (HR 0.927, CI 0.275, 3.120). Additionally, there was no correlation between pulmonary vein reconnection and the mapping parameters. Notably, all patients of group B underwent comprehensive high-density mapping of both the left and right atria, the results of which will be presented. Conclusion Although the primary endpoint defined as freedom from any sustained atrial arrhythmia did not differ between the groups, AF-CAM study gives valuable insight into mechanisms of persistent AF. CFA and DOA mapping provided detailed insights into the regional electrical properties of the atria, underscoring the complex substrate of persistent AF, independent of pulmonary vein reconnection. These findings highlight the need for refined strategies that target the atrial substrate more effectively.Fig 1:Primary endpoint analysis
Willems et al. (2025) studied this question. Re-PVI plus targeted CFA and DOA substrate ablation did not improve 1-year freedom from sustained atrial arrhythmia versus Re-PVI alone in persistent AF patients.